Literature DB >> 12060531

Pharmacokinetics of leflunomide in Chinese healthy volunteers.

Jun Li1, Hong-Wei Yao, Yong Jin, Yun-Fang Zhang, Chang-Yu Li, Yuan-Hai Li, Shu-Yun Xu.   

Abstract

AIM: To study the pharmacokinetics of leflunomide in Chinese healthy volunteers.
METHODS: A single (20, 40, and 60 mg) and 30-d -repeated (20 mg/d) oral doses of leflunomide were performed on 18 (12 males and 6 females) and 6 (4 males and 2 females) Chinese healthy volunteers respectively. A771726, the active metabolite of leflunomide, in serum was determined by high performance liquid chromatography (HPLC). Data were analyzed by a 3p97 program on a Legend computer.
RESULTS: Serum concentration curves of A 771726 in single and repeated oral administration of leflunomide conformed to one compartment model of the first order absorption. Leflunomide was absorbed rapidly with T1/2,ka of between 1.15 h and 2.23 h in single oral administration. The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively. In repeated oral administration, steady stat e concentration was achieved within 30 d. The mean trough concentration was between 32.0 mg/L and 39.7 mg/L. The Cmax, Tmax, AU C0- 24 were (41.5 +/- 2.4) mg/L, (307 +/- 75) h, and (22099 +/- 1234) mg . h . L-1, respectively.
CONCLUSION: The absorption of leflunomide was rapid, and it s elimination was slow after oral administration. The pharmacokinetic results showed that it exhibited first order kinetic characteristics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12060531

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  9 in total

1.  Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.

Authors:  Kyoung-Ah Kim; Hyun-Jin Joo; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2010-10-23       Impact factor: 2.953

2.  Mitochondrial dysfunction induced by leflunomide and its active metabolite.

Authors:  Jiekun Xuan; Zhen Ren; Tao Qing; Letha Couch; Leming Shi; William H Tolleson; Lei Guo
Journal:  Toxicology       Date:  2018-02-08       Impact factor: 4.221

3.  Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis.

Authors:  Jun Shi; Steven J Kovacs; Yaning Wang; Thomas M Ludden; Vijay O Bhargava
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

4.  Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis.

Authors:  Vivien Chan; Bruce G Charles; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

5.  Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects.

Authors:  Xueting Yao; Yiwen Wu; Ji Jiang; Pei Hu; Dongyang Liu; Xia Chen
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

6.  A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells.

Authors:  Hong Wei Yao; Jun Li; Ji Qiang Chen; Shu Yun Xu
Journal:  Inflammation       Date:  2004-04       Impact factor: 4.092

7.  Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.

Authors:  Lei-lei Ma; Zhi-tao Wu; Le Wang; Xue-feng Zhang; Jing Wang; Chen Chen; Xuan Ni; Yun-fei Lin; Yi-yi Cao; Yang Luan; Guo-yu Pan
Journal:  Acta Pharmacol Sin       Date:  2016-01-25       Impact factor: 6.150

8.  Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.

Authors:  Raoul Bergner; Lena Peters; Verena Schmitt; Christian Löffler
Journal:  Clin Rheumatol       Date:  2012-11-22       Impact factor: 2.980

9.  Leflunomide attenuates hepatocyte injury by inhibiting Kupffer cells.

Authors:  Hong-Wei Yao; Jun Li; Ji-Qiang Chen; Shu-Yun Xu
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.